Latest Breaking News On - Cardiac arrhythmia services - Page 3 : comparemela.com

Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up

Pulse Biosciences, Inc. (PLSE), Wednesday announced positive results from the 60-day post-procedure evaluations of four initial patients with atrial fibrillation in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study.

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Pulse Biosciences, Inc. announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully.

Renal HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms